Pall Biotech Integrated Solutions for Gene Therapy

 

Pall have technologies that enable production of viral vectors on a production scale in a relatively small footprint. The statement holds true for both AAV and lent virus. The talk will cover both upstream and downstream technologies starting with seed train all the way through to the final formulation and filling step. With regards to bioreactors we will cover both adherent cell and suspension cell capabilities and projected future movements in the field. We will touch on process development services (PDS) where Pall are able to bring all of their expertise in continuous intensified process development to shorten the path to market for gene therapies.

Speaker

rick morris

Rick Morris, Ph.D.

 

Senior Vice President, R&D

Palll Biotech



Dr. Rick Morris has held many senior-level positions within both the Life Sciences and Industrial lines of business at Pall Corporation, gaining experience in the biopharmaceutical, medical, food & beverage and laboratory markets during his 30-year tenure. In September 2017, he was appointed as a senior vice president of R&D for Pall Biotech, which combines both single use technologies and biopharmaceutical groups, with a specific focus on the rapidly growing field of continuous bioprocessing. In this role Dr. Morris leads internal and external research and development projects on a global basis. He is based in Westborough, MA, USA and has R&D teams in the USA, UK and Belgium.

Pall Biotech Integrated Solutions for Gene Therapy

icon image

Scale Up And Risk Mitigation Of Therapeutic Viral Vectors For Gene Therapy

Register to learn more about scale up and risk mitigation of viral vectors for GT.

더 Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
May 2021
Overcome Exosome Production Challenges

Biotech | Pall Corporation 웨비나 시리즈

This webinar was recorded by BioPharma Asia and first published on their website. https://biopharma-asia.com. It is made available here by kind permission of BioPharma Asia and the presenters. Scroll down to see a transcript of the webinar question and answer session.

 

Hailed as the “next frontier” in cell therapy and regenerative medicine, exosomes are a type of extracellular vesicle and play a key role in the regulation of the intercellular communication processes.

David Haylock of VivaZome will present on upstream production of angiogenic exosomes using the iCELLis® nano fixed bed bioreactor. This will be followed by a presentation by Roberto Ciboldi of Pall Corporation on a platform solution including cell culture, purification and sterile filtration of exosomes.

Participants will be able to:

 

  • Compare the performance of the iCELLis Nano bioreactor to traditional flasks for exosome production from adherent cell culture
  • Understand how an integrated end to end platform delivers highly   purified and consistently-sized exosomes
  • Discover an innovative cGMP scalable manufacturing platform for   exosomes
시청